68 Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas
Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1725-1733
DOI: 10.2967/jnumed.126.272348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 20.08.2026. Verfasst von Anna-Maria Spektor und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Mainz, Mainz, Germany; anna-maria.spektor@unimedizin-mainz.de. Hauptthemen laut MEDLINE: Neurilemmoma, Positron Emission Tomography Computed Tomography, Neurofibroma, Nerve Sheath Neoplasms. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas that can develop either de novo or as a result of malignant transformation of neurofibromas. Diagnostic modalities of choice, such as MRI or 18F-FDG PET/CT, show high sensitivity for the detection of MPNSTs but moderate specificity, as MPNSTs and benign peripheral nerve sheath tumors (BPNSTs) can initially present similar clinical and radiologic pictures. PET/CT with 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) showed specific uptake in sarcomas and enabled differentiation of benign and malignant lesions in other entities. Here, we analyzed the ability of 68Ga-FAPI PET/CT to differentiate between MPNSTs and BPNSTs.
Methods
Twenty-six patients with suspected or histologically confirmed peripheral nerve sheath tumors who were scheduled to have surgical resection/biopsy underwent 68Ga-FAPI-46 PET/CT with static and dynamic acquisition. SUVmax, SUVmean, maximum and mean tumor-to-background ratios, and time-activity curves were evaluated using volume-of-interest-based analysis (isocontour 50%). Time to peak was derived from time-activity curves. Statistical analyses were performed, and receiver-operating-characteristic curves were calculated. Exemplary target validation by fibroblast activation protein immunohistochemistry was performed in 13 cases.
Results
Eighteen patients (4 with MPNSTs, 5 with neurofibromas, 9 with schwannomas) were included in the final analysis. MPNSTs showed significantly higher 68Ga-FAPI uptake compared with BPNSTs. Neurofibromas showed higher 68Ga-FAPI uptake compared with schwannomas. In dynamic imaging, time to peak of MPNSTs and neurofibromas was prolonged compared with schwannomas. Analysis of receiver-operating-characteristic curves displayed high sensitivity (100%) and specificity (92.86%) of 68Ga-FAPI PET/CT for discrimination of MPNSTs and BPNSTs, for an exploratory SUVmax cutoff value of 7.53. Fibroblast activation protein expression was strong in MPNSTs and moderate in BPNSTs.
Conclusion
68Ga-FAPI PET/CT may aid in differentiating between MPNSTs and BPNSTs, thereby improving lesion characterization in indeterminate MRI or 18F-FDG PET/CT scenarios.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Mainz, Mainz, Germany; anna-maria.spektor@unimedizin-mainz.de.
- 3rd Medical Department, University Medical Center Mainz, Mainz, Germany.
- University Cancer Center, University Medical Center Mainz, Mainz, Germany.
- Department of Neuroradiology, University Medical Center Mainz, Mainz, Germany.
- Department of Neurosurgery, University Hospital LMU Munich, Munich, Germany.
- Department of Neurosurgery, University Medical Center Mainz, Mainz, Germany.
Zitieren
APA
Spektor, A. M., Fried, M., Zapata Bonilla, S. A., Othman, A., Kalasauskas, D., Kersting, D., Mildenberger, P., Winter, E., Zimmer, S., Adami, B., Hamacher, R., Waldschütz, A. M., Eckert, C., Conrad, J., Sommer, C., Herrmann, K., Fendler, W. P., Brockmann, M. A., Schreckenberger, M., …, & Röhrich, M. (2026). 68 Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas. Journal of Nuclear Medicine, 67(11), 1725-1733. https://doi.org/10.2967/jnumed.126.272348
Vancouver
Spektor AM, Fried M, Zapata Bonilla SA, Othman A, Kalasauskas D, Kersting D, et al. 68 Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas. Journal of Nuclear Medicine. 2026;67(11):1725-1733. doi:10.2967/jnumed.126.272348
BibTeX
@article{Spektor2026,
author = {Spektor, Anna-Maria and Fried, Marius and Zapata Bonilla, Sergio A and Othman, Ahmed and Kalasauskas, Darius and Kersting, David and Mildenberger, Philipp and Winter, Erik and Zimmer, Stefanie and Adami, Bonny and Hamacher, Rainer and Waldschütz, Anne-Marie and Eckert, Christoph and Conrad, Jens and Sommer, Clemens and Herrmann, Ken and Fendler, Wolfgang P and Brockmann, Marc A and Schreckenberger, Mathias and Haberkorn, Uwe and Kindler, Thomas and Röhrich, Manuel},
title = {68 Ga-FAPI PET/CT for Differentiation of Malignant Peripheral Nerve Sheath Tumors, Neurofibromas, and Schwannomas},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {11},
pages = {1725--1733},
doi = {10.2967/jnumed.126.272348}
}
EUVIMED